Ikarian Capital’s Fulcrum Therapeutics FULC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.66M Sell
449,161
-600,000
-57% -$2.25M 0.17% 113
2026
Q2
$3.84M Hold
1,049,161
– – 0.41% 68
2026
Q1
$8.05M Sell
1,049,161
-326,311
-24% -$3.03M 0.65% 43
2025
Q4
$15.6M Buy
1,375,472
+86,247
+7% +$878K 1.21% 23
2025
Q3
$11.9M Buy
1,289,225
+860,704
+201% +$6.23M 1.2% 21
2025
Q2
$2.95M Buy
428,521
+228,425
+114% +$1.22M 0.57% 54
2025
Q1
$576K Hold
200,096
– – 0.07% 112
2024
Q4
$940K Buy
200,096
+125,096
+167% +$462K 0.13% 110
2024
Q3
$268K Buy
+75,000
New +$556K 0.04% 133
2021
Q3
– Sell
-162,700
Closed -$1.7M – 233
2021
Q2
$1.7M Sell
162,700
-264,039
-62% -$2.67M 0.14% 140
2021
Q1
$5.03M Sell
426,739
-10,961
-3% -$136K 0.17% 118
2020
Q4
$5.12M Buy
+437,700
New +$4.95M 0.23% 92

Other funds holding FULC

Ikarian Capital's FULC Position: Q3 2026 in Review

Ikarian Capital reduced its Fulcrum Therapeutics (FULC) stake by 57% in Q3 2026, selling an estimated $2.25M and leaving 449,161 shares worth $1.66M. The position accounts for 0.17% of the portfolio, ranked #113.

Ikarian Capital first reported a position in FULC in Q4 2020 and has held it in 12 quarters since. The position peaked at $15.6M in Q4 2025. 149 funds tracked by Wall St. Rank hold FULC as of Q3 2026.

  • Ikarian Capital held 449,161 shares of Fulcrum Therapeutics worth $1.66M as of Q3 2026.
  • Ikarian Capital sold 600,000 Fulcrum Therapeutics shares in Q3 2026, an estimated $2.25M.
  • Fulcrum Therapeutics made up 0.17% of Ikarian Capital's portfolio in Q3 2026, its #113 holding.
  • Ikarian Capital first reported a position in Fulcrum Therapeutics in Q4 2020 and has held it in 12 quarters since.
  • Ikarian Capital's Fulcrum Therapeutics position peaked at $15.6M in Q4 2025.
  • 149 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2026.

Based on Ikarian Capital's 13F filing for Q3 2026, filed 16 Nov 2026.